A carregar...
Publicação
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 212.53 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Maraviroc (MVC) is not approved for HIV-1-infected paediatric patients. This is the first assessment of the use of MVC-based salvage therapy in vertically HIV-1-infected paediatric patients in clinical settings. The results suggest that MVC-based salvage therapy is useful in children and adolescents with extensive resistance profile leading to maintained virological suppression in up to 88% of the patients with CCR5-tropic virus. The likelihood of treatment success might increase when MVC is combined with other active drugs.
Descrição
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Palavras-chave
adolescents children HAART HIV-1 maraviroc
Contexto Educativo
Citação
Palladino C, Gómez MLN, Soler-Palacín P, González-Tomé MI, De Ory SJ, Espiau M, et al. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice. AIDS [Internet]. 23 de outubro de 2015;29(16):2155–9. Disponível em: https://journals.lww.com/00002030-201510230-00015
Editora
Wolters Kluwer Health